Investigational drug · Phase 2
bexmarilimab
Also called: FP-1305
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "bexmarilimab"
First trial start
2022
Jun 2, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "bexmarilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Higher Risk Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndromes
- Relapsed/Refractory AML
Approved drugs for the same conditions: Acute myeloid leukemia · Myelodysplastic syndromes · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "bexmarilimab" as an intervention, largest first.
- A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.Pivotal-lookingRecruiting
MedSIRAcademic, hospital or other
NCT07460986 · 278 participants (planned) · Start Aug 20, 2026 · Primary completion Jul 2028
Drug: bexmarilimab; Doxorubicin · For: Soft Tissue Sarcoma (STS)
Sites: Badalona, Spain; Barakaldo, Spain; Barcelona, Spain · 11 sites in all
Faron Pharmaceuticals LtdIndustry
NCT03733990 · 216 participants · Start Dec 3, 2018 · Primary completion Sep 6, 2023
Drug: FP-1305 (bexmarilimab) · For: Cancer
Sites: San Antonio, Texas; Helsinki, Finland; Oulu, Finland · 11 sites in all
- A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological MalignanciesActive, not recruiting
Faron Pharmaceuticals LtdIndustry
NCT05428969 · 181 participants (planned) · Start Jun 2, 2022 · Primary completion Mar 2027
Drug: Bexmarilimab; Azacitidine and 1 more · For: Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes and 1 more
Sites: Duarte, California; New Haven, Connecticut; Chapel Hill, North Carolina · 10 sites in all
Faron Pharmaceuticals LtdIndustry
NCT07672769 · 90 participants (planned) · Start Nov 2026 · Primary completion Nov 2027
Drug: bexmarilimab (1mg/kg); azacitidine and 2 more · For: Higher Risk Myelodysplastic Syndromes
Sites: Duarte, California; Aurora, Colorado; New Haven, Connecticut · 35 sites in all
- Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLCRecruiting
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT07718243 · 62 participants (planned) · Start Aug 28, 2026 · Primary completion Jan 31, 2030
Drug: Bexmarilimab 1mg/kg and nivolumab 1mg/kg; Bexmarilimab 3mg/kg and nivolumab 1mg/kg and 1 more · For: Melanoma (Skin Cancer); Non Small Cell Lung Cancer; Solid Tumor in Advanced Stage
Sites: Manchester, United Kingdom; Sutton, United Kingdom
- Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung CancerWithdrawn
The University of Texas Health Science Center at San AntonioAcademic, hospital or other
NCT05171062 · 0 participants · Start Jun 2023 · Primary completion Dec 2025
Drug: bexmarilimab (FP-1305); Pembrolizumab · For: Non-small Cell Lung Cancer
Sites: San Antonio, Texas
Faron Pharmaceuticals LtdIndustry
NCT05104905 · 0 participants · Start Oct 7, 2021 · Primary completion Jan 28, 2022
Drug: bexmarilimab · For: Carcinoma, Renal Cell; Carcinoma Colon
Sites: Turku, Finland
Newest research
PubMed records naming it or its code names, newest first.
- CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer.
Xiang X, Wang F, Shen Y, et al. · J Immunother Cancer 2025
- Clinical optimization of bexmarilimab as a myeloid checkpoint therapy.
Karthikeyan M, Mickos J, Hollmén M · Immunotherapy 2025
- Correction: Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment.
· J Immunother Cancer 2025
- Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial.
Kontro M, Stein AS, Pyörälä M, et al. · Lancet Haematol 2025
- Secreted Clever-1 modulates T cell responses and impacts cancer immunotherapy efficacy.
Prince S, Viitala M, Sjöroos R, et al. · Theranostics 2025
- Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment.
Rannikko JH, Turpin R, Boström P, et al. · J Immunother Cancer 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.